Bacil Pharma Ltd

As of June 30, 2026, Bacil Pharma Ltd carries a market capitalization of 558.67M, placing it among publicly traded companies globally. Its enterprise value stands at 558.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bacil Pharma Ltd has 13.97M shares outstanding.

As of June 30, 2026, Bacil Pharma Ltd trades at a trailing price-to-earnings ratio of 84.03.

These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Bacil Pharma Ltd recorded an income tax benefit of -4.96M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 1.63M, leaving 6.59M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bacil Pharma Ltd's stock has declined approximately 52.47% over the past 52 weeks. The 50-day moving average sits at 19.01, while the 200-day moving average is 38.19.

Over the twelve months ended June 30, 2026, Bacil Pharma Ltd generated - - in revenue and converted that into 6.59M in net income, yielding earnings per share of 0.48. EBITDA reached -1.59M, while operating income came in at -1.59M.